{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T03:47:29Z","timestamp":1795232849274,"version":"4.10.3"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2022,1,1]]},"DOI":"10.1001\/jamaophthalmol.2021.4576","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T16:15:03Z","timestamp":1637252103000},"page":"11","source":"Crossref","is-referenced-by-count":170,"title":["Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma"],"prefix":"10.1001","volume":"140","author":[{"given":"Carlos Gustavo","family":"De Moraes","sequence":"first","affiliation":[{"name":"Bernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon W. M.","family":"John","sequence":"additional","affiliation":[{"name":"Bernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Columbia University Irving Medical Center, New York, New York"},{"name":"Howard Hughes Medical Institute, Chevy Chase, Maryland"},{"name":"Zuckerman Mind Brain Behavior Institute, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pete A.","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Eye and Vision, Department of Clinical Neuroscience, St Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana M.","family":"Blumberg","sequence":"additional","affiliation":[{"name":"Bernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Cioffi","sequence":"additional","affiliation":[{"name":"Bernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Liebmann","sequence":"additional","affiliation":[{"name":"Bernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"eoi210066r1","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1001\/archopht.120.6.714","article-title":"The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma.","volume":"120","author":"Gordon","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"eoi210066r2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.","volume":"121","author":"Leske","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"eoi210066r3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration.","volume":"130","author":"The AGIS Investigators","year":"2000","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"eoi210066r4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0002-9394(98)00272-4","article-title":"The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma.","volume":"126","author":"Collaborative Normal-Tension Glaucoma Study Group","year":"1998","journal-title":"Am J Ophthalmol"},{"issue":"9975","key":"eoi210066r5","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","article-title":"Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial.","volume":"385","author":"Garway-Heath","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"eoi210066r6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ajo.2010.09.026","article-title":"A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.","volume":"151","author":"Krupin","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"eoi210066r7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/tvst.4.2.1","article-title":"Why do people (still) go blind from glaucoma?","volume":"4","author":"Susanna","year":"2015","journal-title":"Transl Vis Sci Technol"},{"issue":"5","key":"eoi210066r8","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.ajo.2014.02.009","article-title":"Risk factors for optic disc hemorrhage in the low-pressure glaucoma treatment study.","volume":"157","author":"Furlanetto","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"eoi210066r9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/bjophthalmol-2020-316331","article-title":"Low systemic vitamin D as a potential risk factor in primary open-angle glaucoma: a review of current evidence.","volume":"105","author":"Huynh","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"eoi210066r10","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1167\/iovs.19-27099","article-title":"Nicotinamide deficiency in primary open-angle glaucoma.","volume":"60","author":"Kouassi Nzoughet","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"23","key":"eoi210066r11","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25235614","article-title":"Effects of citicoline, homotaurine, and vitamin E on contrast sensitivity and visual-related quality of life in patients with primary open-angle glaucoma: a preliminary study.","volume":"25","author":"Marino","year":"2020","journal-title":"Molecules"},{"issue":"7","key":"eoi210066r12","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/ceo.v48.7","article-title":"Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: a crossover randomized clinical trial.","volume":"48","author":"Hui","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"key":"eoi210066r13","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7879436","article-title":"Assessing the performance of daily intake of a homotaurine, carnosine, forskolin, vitamin B2, vitamin B6, and magnesium based food supplement for the maintenance of visual function in patients with primary open angle glaucoma.","volume":"2020","author":"Rolle","year":"2020","journal-title":"J Ophthalmol"},{"issue":"1","key":"eoi210066r14","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcz035","article-title":"Midget retinal ganglion cell dendritic and mitochondrial degeneration is an early feature of human glaucoma.","volume":"1","author":"Tribble","year":"2019","journal-title":"Brain Commun"},{"issue":"6326","key":"eoi210066r15","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1126\/science.aal0092","article-title":"Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice.","volume":"355","author":"Williams","year":"2017","journal-title":"Science"},{"key":"eoi210066r16","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101988","article-title":"Nicotinamide provides neuroprotection in glaucoma by protecting against mitochondrial and metabolic dysfunction.","volume":"43","author":"Tribble","year":"2021","journal-title":"Redox Biol"},{"issue":"7","key":"eoi210066r17","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.cell.2013.11.037","article-title":"Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging.","volume":"155","author":"Gomes","year":"2013","journal-title":"Cell"},{"key":"eoi210066r18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3389\/fnins.2017.00232","article-title":"Nicotinamide and WLDS act together to prevent neurodegeneration in glaucoma.","volume":"11","author":"Williams","year":"2017","journal-title":"Front Neurosci"},{"issue":"1","key":"eoi210066r19","doi-asserted-by":"crossref","DOI":"10.1080\/19420889.2017.1356956","article-title":"Nicotinamide treatment robustly protects from inherited mouse glaucoma.","volume":"11","author":"Williams","year":"2018","journal-title":"Commun Integr Biol"},{"issue":"19","key":"eoi210066r20","doi-asserted-by":"publisher","first-page":"E3839","DOI":"10.1073\/pnas.1608769114","article-title":"Early immune responses are independent of RGC dysfunction in glaucoma with complement component C3 being protective.","volume":"114","author":"Harder","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"eoi210066r21","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/IJG.0000000000000767","article-title":"Glaucoma as a metabolic optic neuropathy: making the case for nicotinamide treatment in glaucoma.","volume":"26","author":"Williams","year":"2017","journal-title":"J Glaucoma"},{"issue":"52","key":"eoi210066r22","doi-asserted-by":"publisher","first-page":"33619","DOI":"10.1073\/pnas.2014213117","article-title":"Disturbed glucose and pyruvate metabolism in glaucoma with neuroprotection by pyruvate or rapamycin.","volume":"117","author":"Harder","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"eoi210066r23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.10.001","article-title":"Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma.","volume":"56","author":"De Moraes","year":"2017","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"eoi210066r24","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ajo.2011.06.015","article-title":"Clinical evidence for neuroprotection in glaucoma.","volume":"152","author":"Cordeiro","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"eoi210066r25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.survophthal.2017.09.010","article-title":"Glaucoma and the brain: trans-synaptic degeneration, structural change, and implications for neuroprotection.","volume":"63","author":"Lawlor","year":"2018","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"eoi210066r26","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1167\/iovs.12-9476","article-title":"Intervals between visual field tests when monitoring the glaucomatous patient: wait-and-see approach.","volume":"53","author":"Crabb","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"eoi210066r27","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S0161-6420(89)32840-5","article-title":"Assessing the utility of reliability indices for automated visual fields. testing ocular hypertensives.","volume":"96","author":"Bickler-Bluth","year":"1989","journal-title":"Ophthalmology"},{"issue":"11","key":"eoi210066r28","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.ophtha.2017.04.035","article-title":"Evidence-based criteria for assessment of visual field reliability.","volume":"124","author":"Yohannan","year":"2017","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi210066r29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human.","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"issue":"11","key":"eoi210066r30","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s001250051536","article-title":"Safety of high-dose nicotinamide: a review.","volume":"43","author":"Knip","year":"2000","journal-title":"Diabetologia"},{"issue":"10","key":"eoi210066r31","doi-asserted-by":"publisher","first-page":"7097","DOI":"10.1007\/s12035-019-1576-4","article-title":"Higher reliance on glycolysis limits glycolytic responsiveness in degenerating glaucomatous optic nerve.","volume":"56","author":"Jassim","year":"2019","journal-title":"Mol Neurobiol"},{"issue":"2","key":"eoi210066r32","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ajo.2014.11.012","article-title":"Short-term enhancement of visual field sensitivity in glaucomatous eyes following surgical intraocular pressure reduction.","volume":"159","author":"Wright","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"eoi210066r33","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ajo.2014.04.003","article-title":"Visual field improvement in the collaborative initial glaucoma treatment study.","volume":"158","author":"Musch","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"eoi210066r34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ophtha.2015.09.027","article-title":"Trabeculectomy can improve long-term visual function in glaucoma.","volume":"123","author":"Caprioli","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi210066r35","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.survophthal.2020.12.004","article-title":"Improvement in structure and visual function in patients with glaucoma: the possible key to better treatment?","volume":"66","author":"Ahmed","year":"2021","journal-title":"Surv Ophthalmol"},{"issue":"9","key":"eoi210066r36","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1167\/iovs.04-0834","article-title":"Structure-function relations of parasol cells in the normal and glaucomatous primate retina.","volume":"46","author":"Weber","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"eoi210066r37","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1167\/iovs.12-9979","article-title":"Structural and functional abnormalities of retinal ganglion cells measured in vivo at the onset of optic nerve head surface change in experimental glaucoma.","volume":"53","author":"Fortune","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"13","key":"eoi210066r38","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.1167\/iovs.15-17876","article-title":"Altered transport velocity of axonal mitochondria in retinal ganglion cells after laser-induced axonal injury in vitro.","volume":"56","author":"Yokota","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"33","key":"eoi210066r39","doi-asserted-by":"publisher","first-page":"10515","DOI":"10.1073\/pnas.1509879112","article-title":"In vivo imaging of axonal transport of mitochondria in the diseased and aged mammalian CNS.","volume":"112","author":"Takihara","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"eoi210066r40","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1038\/s41598-018-23220-w","article-title":"Impact of different visual field testing paradigms on sample size requirements for glaucoma clinical trials.","volume":"8","author":"Wu","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"eoi210066r41","doi-asserted-by":"publisher","first-page":"18886","DOI":"10.1038\/s41598-019-55345-x","article-title":"Sample size requirements of glaucoma clinical trials when using combined optical coherence tomography and visual field endpoints.","volume":"9","author":"Wu","year":"2019","journal-title":"Sci Rep"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2786482\/jamaophthalmology_de_moraes_2021_oi_210066_1641846886.20971.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T16:12:16Z","timestamp":1642695136000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2786482"}},"subtitle":["A Phase 2 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.4576","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,1]]}}}